CD274 and non-small cell lung carcinoma: In another study involving advanced/metastatic non-small cell lung cancer (NSCLC) patients undergoing treatment with chemotherapy with or without ICI therapy (n = 72), analyses of pre-treatment levels of PD-L1 in EVs and after 9 weeks of treatment revealed a PD-L1 increase in ICI-treated non-responders relative to that in responders [80].